Pattern and Molecular Mechanisms of Cardiac Troponin Release in Conditions Other than Acute Coronary Syndromes

Main Article Content

Kosit Sribhen
Choosri Sribhen


No Abstract


Download data is not yet available.

Article Details

How to Cite
Sribhen, K. ., & Sribhen, C. . (2020). Pattern and Molecular Mechanisms of Cardiac Troponin Release in Conditions Other than Acute Coronary Syndromes. Siriraj Medical Journal, 63(4), 139–142. Retrieved from
Review Article


1. Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task
Force for the Redefinition of Myocardial Infarction. Universal definition
of myocardial infarction. Eur Heart J. 2007 Oct;28(20):2525-38.
2. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction
redefined--a consensus document of The Joint European Society of Cardiology/
American College of Cardiology Committee for the redefinition of
myocardial infarction. J Am Coll Cardiol. 2000 Sep;36(3):959-69.
3. Eggers KM, Lind L, Venge P, Lindahl B. Will the universal definition of
myocardial infarction criteria result in an overdiagnosis of myocardial
infarction? Am J Cardiol. 2009 Mar 1;103(5):588-91.
4. Apple FS, Pearce LA, Smith SW, Kaczmarek JM, Murakami MM. Role
of monitoring changes in sensitive cardiac troponin I assay results for
early diagnosis of myocardial infarction and prediction of risk of adverse
events. Clin Chem. 2009 May;55(5):930-7.
5. Wu AH, Lu QA, Todd J, Moecks J, Wians F. Short- and long-term biological
variation in cardiac troponin I measured with a high-sensitivity
assay : implications for clinical practice. Clin Chem. 2009 Jan;55(1):52-8.
6. Vasile VC, Saenger AK, Kroning JM, Jaffe AS. Biological and analytical
variability of a novel high-sensitivity cardiac troponin T assay. Clin Chem.
2010 Jul;56(7):1086-90.
7. NACB Writing Group, Wu AH, Jaffe AS, Apple FS, Jesse RL, Francis
GL, et al. National Academy of Clinical Biochemistry Laboratory Medicine
Practice Guidelines : Use of cardiac troponin and B-type natriuretic peptide
or N-terminal pro B-type natriuretic peptide for etiologies other than acute
coronary syndromes and heart failure. Clin Chem. 2007 Dec;53(12):2086-
8. Kociol RD, Pang PS, Gheorghiade M, Fonarow GC, OัConnor CM, Felker
GM. Troponin elevation in heart failure. Prevalence, mechanism, and
clinical implications. J Am Coll Cardiol. 2010 Sep 28;56(14):1071-8.
9. Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008 May
10. Nef HM, Moellmann H, Akashi YJ, Hamm CW. Mechanism of stress
(Takotsubo) cardiomyopathy. Nat Rev Cardiol. 2010 Apr;7(4):187-93.
11. Lyon AR, Rees PSC, Prasad S, Poole-Wilson PA, Harding SE. Stress
(Takotsubo) cardiomyopaty: a novel pathophysiological hypothesis to
explain catecholamine-induced acute myocardial stunning. Nat Clin Pract
Cardiovasc Med. 2008 Jan;5(1):22-9.
12. van der Bilt IA, Hasan D, Vandertop WP, Wilde AA, Algra A, Visser
FC, et al. Impact of cardiac complications on outcome after aneurysmal
subarachnoid hemorrhage. A meta analysis. Neurology. 2009 Feb 17;72(7):
13. Song HS, Bach JH, Jin DK, Chung PW, Moon HS, Suh BC, et al. Cardiac
troponin T elevation after stroke : Relationships between elevated serum
troponin T, stroke location, and prognosis. J Clin Neurol. 2008 Jun;4(2):75-
14. Goh YS, Tong KL. Phaeochromocytoma the great mimicker : A case
report. Ann Acad Med Singapore. 2008 Jan;37(1):79-81.
15. Menke-van der Houven van Oordt CW, Twickler TB, van Asperdt FG,
Ackermans P, Timmers HJ, Hermus AR. Phaeochromocytoma mimicking
an acute myocardial infarction. Neth Heart J. 2007;15(7-8):248-51.
16. Schwartz BG, Rezkalla S, Kloner RA. Cardiovascular effects of cocaine.
Circulation. 2010 Dec 14;122(24):2558-69.
17. Egred M, Davis GK. Cocaine and the heart. Postgrad Med J. 2005 Sep;81
18. Gray SD, Fatovich DM, McCoubrie DL, Daly FF. Amphetamine-related
presentations to an inner-city tertiary emergency department: a prospective
evaluation. Med J Aust. 2007 Apr 2;186(7):336-9.
19. Turnipseed SD, Richards JR, Kirk JD, Diercks DB, Amsterdam EA.
Frequency of acute coronary syndrome in patients presenting to the
emergency department with chest pain after methamphetamine use. J
Emerg Med. 2003 May;24(4):369-73.
20. Regwan S, Hulten EA, Martinho S, Slim J, Villines TC, Mitchell J, et al.
Marathon running as a cause of troponin elevation : A systemic review
and meta-analysis. J Interv Cardiol. 2010 Oct;23(5):443-50.
21. Shave R, Baggish A, George K, Wood M, Scharhag J, Whyte G, et al.
Exercise-induced cardiac troponin elevation. Evidence, mechanisms, and
implications. J Am Coll Cardiol. 2010 Jul 13;56(3):169-76.
22. Sribhen K, Sribhen C. Stress-related myocardial damage and dysfunction :
Biochemical and pathophysiological considerations. Siriraj Med J 2008:
Jan-Feb 60(1): 46-50.
23. Mann DL, Kent RL, Parsons B, Cooper G. Adrenergic effects on the
biology of the adult mammalian cardiocyte. Circulation. 1992 Feb;85(2):
24. Bertinchant JP, Robert E, Polge A, Marty-Double C, Fabbro-Peray P,
Poirey S, et al. Comparison of the diagnostic value of cardiac troponin I
and T determinations for detecting early myocardial damage and the relationship
with histological findings after isoprenaline-induced cardiac injury
in rats. Clin Chim Acta. 2000 Aug;298(1-2):13-28.
25. Abraham J, Mudd JD, Kapur N, Klein K, Champion HC, Wittstein IS.
Stress cardiomyopathy after intravenous administration of catecholamines
and beta-receptor agonists. J Am Coll Cardiol. 2009 Apr 14;53(15):1320-5.
26. Bybee KA, Kara T, Prasad A, Lerman A, Barsness GW, Scott Wright R,
et al. Systemic review : transient left ventricular apical ballooning : a
syndrome that mimics ST-segment elevation myocardial infarction. Ann
Intern Med. 2004 Dec 7;141(11):858-65.
27. Wittstein IS, Thiemann DR, Lima JAC, Baughman KL, Schulman SP,
Gerstenblith G, et al. Neurohumoral features of myocardial stunning due
to sudden emotional stress. N Engl J Med. 2005 Feb 10;352(6):539-48.
28. Mann DL. Basic mechanisms of disease progression in the failing heart :
the role of excessive adrenergic drive. Prog Cardiovasc Dis. 1998 Jul-Aug;
41(1 Suppl 1):1-8.
29. Feldman AM, McNamara D. Myocarditis. N Engl J Med. 2000 Nov 9;343
30. Oakley CM. Myocarditis, pericarditis, and other pericardial diseases. Heart.
2000 Oct;84(4):449-54.
31. Altmann DR, Korte W, Maeder MT, Fehr T, Haager P, Rickli H, et al.
Elevated cardiac troponin I in sepsis and septic shock : No evidence for
thrombus associated myocardial necrosis. PLoS ONE 2010 Feb; 5(2):
32. Wu AHB. Increased troponin in patients with sepsis and septic shock :
myocardial necrosis or reversible myocardial depression? Intensive Care
Med. 2001;27:959-61.
33. Oppeltz RF, Zhang Q, Rani M, Sasaki JR, Schwacha MG. Increased
expression of cardiac IL-17 after burn. J Inflamm (Lond). 2010 Jul 27;
34. Barber RC, Maass DL, White DJ, Horton JW. Increasing percent burn is
correlated with increasing inflammation in an adult rodent model. Shock.
2008 Oct;30(4):388-93.
35. Cardinale D, Sandri MT. Role of biomarkers in chemotherapy-induced
cardiotoxicity. Prog Cardiovasc Dis. 2010 Sep-Oct;53(2):121-9.
36. Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G,
et al. Prognostic value of troponin I in cardiac risk stratification of cancer
patients undergoing high-dose chemotherapy. Circulation. 2004 Jun 8;109
37. Sawyer DB, Peng X, Chen B, Pentassuglia L, Lim CC. Mechanisms of
anthracycline cardiac injury : can we identify strategies for cardioprotection?
Prog Cardiovasc Dis. 2010 Sep-Oct;53(2):105-13.
38. Giroir BP, Horton JW, White DJ, McIntyre KL, Lin CQ. Inhibition of
tumor necrosis factor prevents myocardial dysfunction during burn shock.
Am J Physiol. 1994 Jul;267(1 Pt 2):H118-24.
39. Adamcova M, Simunek T, Kaiserova H, Popelova O, Sterba M, Potacova
A, et al. In vitro and in vivo examination of cardiac troponins as biochemical
markers of drug-induced cardiotoxicity. Toxicology. 2007 Jul
40. Nie J, Close G, George KP, Tong TK, Shi Q. Temporal association of
elevations in serum cardiac troponin T and myocardial oxidative stress
after prolonged exercise in rats. Eur J Appl Physiol. 2010 Dec;110(6):1299-
41. Wagner KH, Reichhold S, Hoelzl C, Knasmueller S, Nics L, Meisel M,
et al. Well-trained, healthy triathletes experience no adverse health risks
regarding oxidative stress and DNA damage by participating in an ultraendurance
event. Toxicology. 2010 Dec 5;278(2):211-6.